JP2009510129A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510129A5
JP2009510129A5 JP2008533792A JP2008533792A JP2009510129A5 JP 2009510129 A5 JP2009510129 A5 JP 2009510129A5 JP 2008533792 A JP2008533792 A JP 2008533792A JP 2008533792 A JP2008533792 A JP 2008533792A JP 2009510129 A5 JP2009510129 A5 JP 2009510129A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
agent
modulator
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008533792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510129A (ja
JP5517454B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/038823 external-priority patent/WO2007041632A2/en
Publication of JP2009510129A publication Critical patent/JP2009510129A/ja
Publication of JP2009510129A5 publication Critical patent/JP2009510129A5/ja
Application granted granted Critical
Publication of JP5517454B2 publication Critical patent/JP5517454B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008533792A 2005-09-30 2006-10-02 Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物 Expired - Fee Related JP5517454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72267905P 2005-09-30 2005-09-30
US60/722,679 2005-09-30
US78754906P 2006-03-29 2006-03-29
US60/787,549 2006-03-29
PCT/US2006/038823 WO2007041632A2 (en) 2005-09-30 2006-10-02 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection

Publications (3)

Publication Number Publication Date
JP2009510129A JP2009510129A (ja) 2009-03-12
JP2009510129A5 true JP2009510129A5 (https=) 2009-11-19
JP5517454B2 JP5517454B2 (ja) 2014-06-11

Family

ID=37906852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533792A Expired - Fee Related JP5517454B2 (ja) 2005-09-30 2006-10-02 Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物

Country Status (13)

Country Link
US (1) US7754685B2 (https=)
EP (1) EP1933859A2 (https=)
JP (1) JP5517454B2 (https=)
KR (1) KR20080059270A (https=)
CN (1) CN105169369B (https=)
AU (1) AU2006299426B2 (https=)
BR (1) BRPI0616476A2 (https=)
CA (1) CA2623865A1 (https=)
IL (1) IL190478A0 (https=)
NZ (1) NZ567262A (https=)
RU (1) RU2440822C2 (https=)
WO (1) WO2007041632A2 (https=)
ZA (1) ZA200803493B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
EP1931696B1 (en) * 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
CN101502196A (zh) * 2006-06-02 2009-08-05 克洛德·安妮·佩里西恩 激活电子的管理
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
EP2142215B1 (en) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of hcv infection
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CN102083852A (zh) * 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
KR101068160B1 (ko) * 2008-12-30 2011-09-27 건국대학교 산학협력단 Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
MX2011007194A (es) * 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2013010946A2 (en) 2011-07-15 2013-01-24 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests i
RU2639388C1 (ru) * 2016-10-11 2017-12-21 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Композиция для терапии вирусного гепатита С
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
AU2021256222A1 (en) * 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863550A (en) * 1993-03-31 1999-01-26 Tokyo Tanabe Company Limited Cholestasis ameliorant
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
PL324531A1 (en) * 1995-07-17 1998-06-08 Chem Ag C Derivatives of cyclosporin effective against hiv virus
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
CN1205220C (zh) * 1998-06-12 2005-06-08 斯－凯穆公司 新颖的环孢菌素
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
EP0982035B1 (en) * 1998-08-18 2004-03-31 Panacea Biotec Limited Cyclosporin composition comprising an hydrophilic carrier
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
DK1385870T3 (da) * 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AP2004003069A0 (en) * 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
US20060025267A1 (en) * 2004-07-29 2006-02-02 Mircea Gradu Differential with torque vectoring capabilities
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
DK1793844T3 (da) * 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
AU2005322241B2 (en) 2004-12-23 2010-02-18 Novartis Ag Compounds for flaviviridae treatment
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1931696B1 (en) * 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes

Similar Documents

Publication Publication Date Title
JP2009510129A5 (https=)
RU2008117157A (ru) Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с
JP5578853B2 (ja) ウイルス感染の治療のための化合物、及び医薬組成物
JP2013521279A5 (https=)
ES2354282T3 (es) Análogos peptídicos inhibidores de la hepatitis c.
ES2290425T3 (es) Tripeptidos heterociclicos en calidad de inhibidores de la hepatitis c.
JP2010508361A5 (https=)
JP5254964B2 (ja) 抗ウイルス剤としての大環状化合物
US6642204B2 (en) Hepatitis C inhibitor tri-peptides
JP2016503800A5 (https=)
JP2013514359A5 (https=)
JP2010509376A5 (https=)
JP2012504632A5 (https=)
JP2010508362A5 (https=)
AU2003202348A1 (en) Heterocyclic tripeptides as hepatitis c inhibitors
US20030186895A1 (en) Hepatitis C inhibitor tri-peptides
JP2014504643A5 (https=)
ZA200405639B (en) Macrocyclic peptides active against the hepatitis C virus.
JP2007535491A5 (https=)
AU2003202347A1 (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of NS3 (Hepatitis C)
ZA200100972B (en) Hepatituis C inhibitor peptides.
US20050159345A1 (en) Composition for the treatment of infection by Flaviviridae viruses
JP2010508360A5 (https=)
WO2003064456A1 (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
JP2015512860A5 (https=)